Simple night time airflow control device eases persistent asthma symptoms

A simple device that filters out airborne asthma triggers during sleep can ease persistent symptoms of the condition during the day and improve quality of life, suggests research published online in Thorax.

Temperature controlled laminar airflow treatment, or TLA for short, delivers a constant, slightly cooled airflow in the patient's breathing area, which displaces warmer air containing irritants and , such as house dust mite and pet hairs.

The aim is to stave off the abnormal that triggers a systemic allergic reaction, including the airway narrowing typical of an , by preventing the sleeper breathing in the irritants and allergens.

The authors base their findings on 281 non-smokers (either passive or active), aged between 7 and 70, from six European countries. All of them had poorly controlled atopic (allergic) asthma.

Of these, 189 slept with a TLA device (Protexo) just above their bed for a year. The remainder were given a dummy device.

A validated score was used to assess quality of life before and after the 12-month study period, in conjunction with assessments of symptom control, , , and biological indicators of a systemic .

The results showed a significant difference of 14-15% on quality of life scores between those using Protexo and those using the dummy device.

A steeper fall in nitric oxide - an indicator of inflammation - was seen among those using Protexo, and this was particularly noticeable among those with more severe asthma. Those using this device also had significantly smaller increases in another indicator of persistent and more severe inflammation - immunoglobulin E (IgE).

The impact was greatest among those whose asthma required the most medication yet whose symptoms were the most poorly controlled, a group who "represent a significant area of unmet need," say the authors.

Despite advances in the treatment of asthma, the condition is still very distressing for a significant proportion of patients, they explain. Previous attempts to filter or purify have not met with a great deal of success.

"The reason that nocturnal TLA is successful where so many other approaches have failed may be the profound reduction in inhaled aeroallergen exposure, which this treatment achieves," they suggest.

They point to other research suggesting that night time allergen exposure has the greatest impact on symptom severity, possibly because of changes in circulating hormone levels and immune responsiveness prompted by the body's internal clock (circadian rhythms).

add to favorites email to friend print save as pdf

Related Stories

Treatment for mild asthma leads to improved lung function

Mar 10, 2008

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day–to-day ...

Antibiotic treatment targets difficult asthma

Dec 17, 2007

Hunter researchers have shown that a commonly available antibiotic can improve the quality of life of patients with difficult asthma, and may also generate significant health care savings.

Recommended for you

Sierra Leone streets deserted as shutdown begins

6 hours ago

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

8 hours ago

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

Cooling of dialysis fluids protects against brain damage

20 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

21 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

User comments